Scientists have developed a new method to potentially enhance the ability of the body's immune cells to fight cancer for extended periods. Researchers at the UCLA Health Jonsson Comprehensive Cancer Center discovered that temporarily increasing the activity of the p53 protein aided specially prepared immune cells in remaining stronger and more effective at killing cancer cells in laboratory settings.
The study, published in Frontiers in Immunology, focused on T cells, a crucial component of the immune system's defense against disease. Some cancer treatments involve modifying a patient's T cells in a lab to recognize and attack tumors before returning them to the body. A significant challenge with these therapies is that the T cells can become "exhausted," diminishing their cancer-fighting capabilities over time.
To address this, the UCLA team treated human T cells with an experimental drug called navtemadlin. This drug temporarily boosts the activity of p53, a protein recognized for its role in preventing cancer. The treated T cells exhibited fewer signs of exhaustion, maintained higher energy levels, and developed characteristics that could potentially prolong their effectiveness.
When these treated T cells were tested against melanoma cells in the lab, they proved substantially more effective at eliminating the cancer cells compared to untreated T cells, according to the findings.
Kien Vuu, a physician and former UCLA assistant clinical professor who was not involved in the research, confirmed that T-cell exhaustion is a major hurdle for these types of treatments. Vuu noted that the practical advantage of this approach is its simplicity, as it involves adding a drug during the lab preparation phase of T cells rather than requiring further genetic modification.
While promising, the findings are preliminary. The experiments were conducted using human cells in a laboratory environment, not in animal models or human patients. Further research, including animal studies and clinical trials, will be necessary to validate the approach.
An important consideration highlighted by the research is the precise dosing of the drug. The UCLA researchers observed that higher doses of navtemadlin led to increased T cell death, whereas lower doses achieved the desired anti-cancer effects without significantly reducing the number of healthy cells. Vuu emphasized that finding the correct balance in p53 activation will be critical for the treatment's success.
While this new direction is considered promising, patients should not expect it to be available in clinics in the immediate future. Researchers are continuing to explore its potential, particularly for treating solid tumors, and are investigating how to optimize dosing for maximum benefit and minimal toxicity.